Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis

Forendo Pharma Successfully Completes Phase 1a Clinical Trial of FOR-6219 for the Treatment of Endometriosis

Turku, Finland, March 07 2019: Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has successfully completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis. The randomised, double-blind, placebo-controlled study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR-6219 in 36 healthy postmenopausal women

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH